Health

Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP

Name: Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP by country, 2020
Creator: World Health Organization, Global Health Observatory (GHO)
License: https://www.who.int/about/policies/publishing/data-policy/terms-and-conditions

· higher is better · 94 countries

Year

World Health Organization, Global Health Observatory (GHO)WHO data terms — CC BY 4.0 asserted at data.who.int; CC BY-NC-SA 3.0 IGO per WHO data policy (display tier, pending clearance)updated 2020

JSON CSV

56 countries · 2020

56 of 56

Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP league table
#	Country		Region	Income
1	China	15.2	East Asia & Pacific	Upper middle income
2	Belize	12.5	Latin America & Caribbean	Upper middle income
3	Malaysia	6.8	East Asia & Pacific	Upper middle income
4	Japan	3.7	East Asia & Pacific	High income
5	Singapore	2.2	East Asia & Pacific	High income
6	United Arab Emirates	1.8	Middle East, North Africa, Afghanistan & Pakistan	High income
7	Bahrain	1.7	Middle East, North Africa, Afghanistan & Pakistan	High income
8	Canada	1.4	North America	High income
9	Bhutan	1	South Asia	Lower middle income
10	Switzerland	0.7	Europe & Central Asia	High income
11	Belgium	0.6	Europe & Central Asia	High income
12	New Zealand	0.1	East Asia & Pacific	High income
13	Australia	0.01	East Asia & Pacific	High income
14	Poland	0	Europe & Central Asia	High income
15	Hungary	0	Europe & Central Asia	High income
16	Philippines	0	East Asia & Pacific	Upper middle income
17	United States	0	North America	High income
18	Austria	0	Europe & Central Asia	High income
19	India	0	South Asia	Lower middle income
20	Ireland	0	Europe & Central Asia	High income
21	Iceland	0	Europe & Central Asia	High income
22	Peru	0	Latin America & Caribbean	Upper middle income
23	Argentina	0	Latin America & Caribbean	Upper middle income
24	Italy	0	Europe & Central Asia	High income
25	Portugal	0	Europe & Central Asia	High income
26	Colombia	0	Latin America & Caribbean	Upper middle income
27	Costa Rica	0	Latin America & Caribbean	High income
28	Slovenia	0	Europe & Central Asia	High income
29	Slovak Republic	0	Europe & Central Asia	High income
30	Chile	0	Latin America & Caribbean	High income
31	Czechia	0	Europe & Central Asia	High income
32	El Salvador	0	Latin America & Caribbean	Upper middle income
33	Germany	0	Europe & Central Asia	High income
34	Sweden	0	Europe & Central Asia	High income
35	Denmark	0	Europe & Central Asia	High income
36	Spain	0	Europe & Central Asia	High income
37	Netherlands	0	Europe & Central Asia	High income
38	Finland	0	Europe & Central Asia	High income
39	Qatar	0	Middle East, North Africa, Afghanistan & Pakistan	High income
40	Thailand	0	East Asia & Pacific	Upper middle income
41	Paraguay	0	Latin America & Caribbean	Upper middle income
42	Brazil	0	Latin America & Caribbean	Upper middle income
43	France	0	Europe & Central Asia	High income
44	Uganda	0	Sub-Saharan Africa	Low income
45	United Kingdom	0	Europe & Central Asia	High income
46	Greece	0	Europe & Central Asia	High income
47	Guatemala	0	Latin America & Caribbean	Upper middle income
48	Oman	0	Middle East, North Africa, Afghanistan & Pakistan	High income
49	South Africa	0	Sub-Saharan Africa	Upper middle income
50	Zambia	0	Sub-Saharan Africa	Lower middle income
51	Malta	0	Middle East, North Africa, Afghanistan & Pakistan	High income
52	Mauritius	0	Sub-Saharan Africa	Upper middle income
53	Malawi	0	Sub-Saharan Africa	Low income
54	Nicaragua	0	Latin America & Caribbean	Lower middle income
55	Norway	0	Europe & Central Asia	High income
56	Lao PDR	0	East Asia & Pacific	Lower middle income

Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP